The Joe Rogan ExperienceJoe Rogan Experience #1246 - Pot Debate - Alex Berenson & Dr. Michael Hart
CHAPTERS
- 0:04 – 4:58
Setting the stage: benefits, risks, and why this debate matters
Joe introduces the guests and frames the conversation as a search for nuance: cannabis has real benefits, but it’s not harmless for everyone. Early anecdotes about edibles and vaping set up the core tension—population-level claims vs individual adverse reactions.
- •Guest introductions: Dr. Michael Hart (cannabis medicine) and Alex Berenson (author of a critical cannabis book)
- •Joe acknowledges personal advocacy while emphasizing variability in reactions
- •Anecdotes of prolonged, destabilizing highs from high-potency products
- •Hart’s framing: cannabis should be treated like any medicine—risks and benefits, patient selection
- 4:58 – 8:44
Is cannabis safer than alcohol? Deaths, attribution, and “associated” harms
The discussion quickly turns to comparing cannabis and alcohol harms. Hart argues cannabis has no direct lethal dose deaths, while Berenson argues “associated” harms (suicide, violence, accidents) are undercounted for cannabis and could be substantial if measured like alcohol.
- •Hart: zero direct overdose deaths vs large alcohol mortality
- •Berenson: alcohol death statistics include many ‘associated’ causes; cannabis should be counted similarly
- •Debate over THC testing (active vs inactive metabolites) and causality limits
- •Cannabis characterized as potentially neurotoxic for some; alcohol as physically toxic
- 8:44 – 10:23
THC vs CBD: why cannabis isn’t one thing (munchies, receptors, and THCV)
Hart emphasizes separating psychoactive THC from non-intoxicating CBD, including different physiological mechanisms and use cases. He explains appetite effects via CB1/ghrelin and mentions THCV as a possible appetite-reducing cannabinoid.
- •Distinction between ‘cannabis’ broadly vs high-THC products specifically
- •CB1 receptor, ghrelin, and why THC can increase appetite
- •THC side effects can be beneficial in wasting/chemotherapy contexts
- •THCV introduced as a cannabinoid that may reduce appetite
- 10:23 – 13:48
Medical vs recreational reality: who seeks cannabis care and what ‘medicine’ means
Berenson challenges whether most cannabis use is truly medical; Hart replies that legalization in Canada separates recreational buying from medical consultations. They debate the legitimacy of ‘pot doctor’ authorizations and whether the medical framing was used as a pathway to legalization in the U.S.
- •Berenson: most THC use is recreational; calling it ‘medicine’ misleads
- •Hart: in Canada, medical patients are more clearly self-selected because recreational access is easy
- •Critique of U.S. medical authorization practices and variable clinic standards
- •Joe notes the historic “backdoor” medical route to legalization
- 13:48 – 18:12
Evidence standards clash: anecdotes vs randomized trials (and what THC actually treats)
Berenson argues that many THC claims fail under randomized controlled trials and that FDA-style evidence has been bypassed. Hart and Joe counter with barriers to research and narrower but meaningful indications, while pushing for better studies rather than blanket dismissal.
- •Berenson: clinical trials are the core test; many THC/cannabis trials show limited efficacy
- •Joe: historical/political barriers (federal illegality) constrained research
- •Debate over indications: chemotherapy nausea, seizures (CBD), pain, and more speculative claims (cancer, Alzheimer’s, IBS)
- •Agreement in principle: allow proper phase trials for cannabinoids
- 18:12 – 27:35
PTSD and the endocannabinoid system: Hart’s clinician argument for THC/CBD
Hart makes a mechanistic and clinical case for cannabis in PTSD: reduced nightmares (THC/Nabilone), fear learning modulation (CBD), and deficiencies in endocannabinoids like anandamide. Berenson appreciates the clinical motivation but insists population guidance needs stronger evidence.
- •Nabilone (synthetic THC) cited for reducing PTSD nightmares
- •Mechanism discussion: anandamide levels and CB1 signaling
- •Clinician vs epidemiologist roles: helping individuals vs setting broad policy
- •Hart leans on patient outcomes and limited effectiveness of existing PTSD medications
- 27:35 – 29:46
Accusations of selective citation: the National Academies report and ‘not balanced’ writing
Hart argues Berenson cherry-picks from authoritative sources and omits qualifying findings (like cognitive outcomes in psychotic disorders). Berenson defends quoting the report’s plain language on psychosis risk and openly states his book is intentionally not balanced to correct what he sees as one-sided advocacy.
- •Hart cites a committee member’s criticism: report did not ‘conclude cannabis causes schizophrenia’
- •Berenson: the report states association and dose-response; he quoted accurately
- •Joe presses on why positive/qualifying statements were excluded
- •Berenson acknowledges: the book aims to emphasize under-discussed harms
- 29:46 – 43:41
Schizophrenia rates, data quality, and what we can’t measure in the U.S.
A major dispute emerges over whether schizophrenia/psychosis rates have risen alongside cannabis use. Berenson argues U.S. data is too poor to know trends, citing changes in NIMH estimates and better registry-based evidence from Northern Europe; Hart points to stable or lower baseline estimates and age-related vulnerability.
- •Hart: risk signals are strongest for adolescent use; Canada uses conservative ‘under 25’ guidance
- •Berenson: U.S. can’t reliably count schizophrenia; only some European countries can
- •Denmark/Finland discussed as places showing increases alongside rising cannabis use historically
- •Debate over correlation vs causation and alternative environmental factors
- 43:41 – 1:18:04
Social media vs cannabis as drivers of youth distress: suicide stats and interpretation fights
Joe and Hart argue social media pressure is a major driver of anxiety, depression, and suicidality, while Berenson says the largest distress jump appears in 18–25 rather than 12–17 and warns against intuitive narratives unsupported by broad behavioral trends. They scrutinize teen suicide rates, relative vs absolute risk, and how endpoints like death miss broader suffering.
- •Joe cites Jonathan Haidt: rising depression/suicide among young girls correlated with social media
- •Berenson: teens show healthier behavior trends overall; distress increase is clearer in 18–25
- •Argument over absolute numbers vs percentage increases in suicide rates
- •Agreement that multiple factors could coexist (social media, opioids, cannabis, life stress)
- 1:18:04 – 1:28:57
Potency, tolerance, and edibles as ‘psychedelic’: why dosing goes wrong
The conversation shifts to modern high-potency products and why they can overwhelm inexperienced users. Joe and Berenson agree cannabis affects people very differently, tolerance can be extreme, and edibles—via 11-hydroxy-THC—can produce intense, prolonged, psychedelic-like experiences that demand better education.
- •Why consumers chase potency: tolerance escalation and habituation
- •Sober breaks reset sensitivity; heavy users can consume huge doses
- •Edibles produce 11-hydroxy-THC and can last much longer than smoked effects
- •Joe’s paradoxical view: occasional paranoia can be introspective for him, but not for everyone
- 1:28:57 – 1:41:21
From paranoia to psychosis: real-world break stories and the ‘trigger’ debate
Berenson recounts parent stories of catastrophic, lasting psychosis after cannabis—especially among young men—while Joe and Hart note some people may have developed schizophrenia regardless. They converge on a practical point: for vulnerable individuals, cannabis can be a dangerous trigger and discouraging use is crucial.
- •Severe case example: rapid decline into persistent schizophrenia and homelessness
- •Debate: cannabis as trigger vs inevitable onset; the ‘window’ of typical onset age for males
- •Hart: functional decline can occur without cannabis due to stress/prodrome
- •Consensus: some individuals should not use THC; vulnerability screening matters
- 1:41:21 – 2:48:30
Violence claims and legalization-era crime data: association, confounds, and ‘what counts’
The final segment becomes a detailed argument over whether cannabis contributes to violence and whether legalization affects crime rates. Berenson emphasizes psychosis-mediated violence and cites increases in murders/aggravated assaults in early-legal states, while Hart challenges causality, points to broader reviews, and highlights confounders like migration, organized crime, guns, and socioeconomic conditions.
- •Berenson’s mechanism: psychosis/paranoia elevates risk; untreated + substance use is most dangerous
- •Hart cites meta-analyses/reviews where cannabis-specific links are unclear vs alcohol/polysubstance
- •Dispute over state-level trends (2013–2017) and what datasets/counting methods should be used
- •Alternative explanations: population influx, cash-based dispensary risks, black-market exporting, gun prevalence
- •Shared end note: U.S. novelty/high potency plus poor education may amplify harms during legalization transition
